Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI